Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VBI Vaccines
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Large Molecule
- Other Names / Subsidiaries
- Variation Biotechnologies